Eczema (atopic dermatitis) is a chronic inflammatory skin condition causing itchy, inflamed patches that can significantly disrupt sleep and quality of life. Research has accelerated rapidly, with several new drug classes now approved and more in trials — making this one of the most active areas in dermatology.
What's actually going on in research
Dupilumab, which blocks IL-4 and IL-13 signaling, transformed treatment for moderate-to-severe eczema and remains the reference point against which newer drugs are compared. JAK inhibitors targeting the itch and inflammation pathways are now available in topical and oral forms, and trials are expanding their use in different age groups. Tralokinumab and lebrikizumab offer additional IL-13-specific options, and combination approaches with allergen immunotherapy are being explored.
JAK inhibitors
Oral and topical JAK inhibitors block the intracellular signaling that drives itch and skin inflammation. Trials are testing them in children, in flare prevention, and in combination with biologics.
Next-generation biologics
Drugs targeting IL-13 specifically (tralokinumab, lebrikizumab) or broader Th2 pathways are being compared head-to-head with dupilumab to find the best match for different patient profiles.
Allergen immunotherapy
Trials are testing whether structured allergen desensitization alongside biologic therapy reduces eczema severity in patients with documented environmental or food allergen sensitivities.
What to know before you search
Eligibility typically requires moderate-to-severe eczema by EASI or IGA score, inadequate response to topical treatments, and sometimes specific IgE or biomarker levels.
What types of trials are currently open
- Drug trials — Testing new biologics, JAK inhibitors, or topical agents for moderate-to-severe atopic dermatitis.
- Pediatric trials — Evaluating safety and dosing of newer treatments specifically in infants, children, and adolescents.
- Prevention trials — Testing early skin barrier interventions and emollient use in high-risk newborns to prevent eczema development.
- Comorbidity trials — Studying whether treating eczema reduces the atopic march to asthma and allergic rhinitis.
- Behavioral trials — Testing itch-scratch cycle interventions, habit reversal training, and sleep improvement programs.
Recently added Eczema trials
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636. The results are intended to support the further clinical development of DCY636 in future studies.
Find Eczema trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.